Tariff Consultant for Boston Biotech, Pharma and Seafood Importers

Peacock Tariff Consulting works with Boston-area biotech and pharma importers (Cambridge cluster), medical device makers, and the New England seafood complex. We focus on Section 232 pharma readiness, biotech raw material HTS, medical-device classification, and seafood AD/CVD exposure. Independent of any brokerage; structured for SMB importers in the $20M-$500M revenue band.

Boston is the U.S. biotech and pharma capital – Cambridge’s Kendall Square is the densest concentration of biotech firms in the world. With Section 232 pharma effective July 31, 2026 and the MedTech Section 232 investigation in flight, Boston importers face among the highest sectoral tariff exposure in the country. Add the seafood complex at Boston Fish Pier and the medical-device makers across Greater Boston, and you have a market that needs specialty tariff advisory.

Peacock Tariff Consulting works with Boston-area biotech, pharma, MedTech, and seafood importers. Our practice runs through Section 232 readiness, HTS classification for specialty inputs, and FDA/CBP regulatory overlap.

Biotech raw material HTS – the Cambridge specialty

Biotech importers bring in research-grade chemicals, cell culture media, specialty enzymes, and instruments. Classification across Chapter 28-30 (chemicals, pharmaceuticals) and Chapter 38 (miscellaneous chemical products) requires specialty knowledge – and the duty differences across boundary subheadings can be 5-15% even before Section 122 stacking.

For Cambridge biotech firms and adjacent specialty chemical importers, classification audits regularly identify duty optimization opportunities.

Section 232 pharma readiness

Section 232 pharmaceutical tariffs take effect July 31, 2026 with tiered rates. Generics and biosimilars are excluded under the current proclamation. Boston-area pharma importers – particularly mid-market specialty pharma firms – face exposure on branded patented drugs and certain APIs.

Readiness work: HTS classification scope confirmation, tier-rate exposure modeling, supplier shift analysis (Ireland and Switzerland are common alternatives with their own implications).

Medical-device classification – FDA / CBP overlap

Medical devices sit at the intersection of HTS classification and FDA regulatory categorization. Devices classified under FDA Class I, II, or III have distinct CBP entry treatments, and the HTS subheading interacts with FDA filing requirements.

For Massachusetts MedTech firms ($10M-$200M revenue), our work covers HTS classification verification, FDA-CBP coordination, and Section 232 MedTech probe readiness as that investigation develops.

Seafood imports – AD/CVD and origin

Boston Fish Pier and the New England seafood complex face active antidumping and countervailing duty orders on multiple species – particularly shrimp, crayfish, and certain fish products. AD/CVD scope rulings and country-of-origin determinations drive significant cost differences.

For SMB seafood importers, our work covers AD/CVD scope verification, origin documentation review, and protest filings where AD/CVD is misapplied.

Conley Terminal FTZ

Conley Terminal is the only full-service container terminal serving 14M New England consumers. FTZ activation around the Conley footprint provides duty deferral and Section 122 avoidance for high-volume importers running New England distribution.

Frequently asked questions

Do you work with Cambridge biotech firms?

Yes – that is a core engagement profile for our Boston practice. Specialty chemical and biotech raw material classification, Section 232 readiness, and FDA-CBP regulatory coordination.

Can you help with Section 232 pharma exposure modeling?

Yes. Section 232 pharma readiness reviews are fixed-fee engagements covering scope confirmation, tier-rate modeling, and supplier shift analysis. Especially relevant for branded pharma firms before the July 31 effective date.

How do AD/CVD orders affect Boston seafood importers?

AD/CVD orders can add duty rates of 100%+ on top of normal rates for specific species and origins. Scope rulings determine whether your specific product falls under an order. Misapplied AD/CVD is protestable; properly applied AD/CVD requires alternative sourcing.

What is the FDA / CBP coordination issue for medical devices?

Medical devices need both FDA admissibility (registration, listing, premarket clearance where required) and CBP entry compliance. Conflicts arise when FDA and CBP categorizations diverge or when entry timing creates regulatory gaps.

Are you affiliated with Massport or MassBio?

No. We are independent. We attend industry events and have presented at MassBio meetings but maintain no affiliations.